Cargando…

LOX-1, OxLDL, and Atherosclerosis

Oxidized low-density lipoprotein (OxLDL) contributes to the atherosclerotic plaque formation and progression by several mechanisms, including the induction of endothelial cell activation and dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation. Vascular wal...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirillo, Angela, Norata, Giuseppe Danilo, Catapano, Alberico Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723318/
https://www.ncbi.nlm.nih.gov/pubmed/23935243
http://dx.doi.org/10.1155/2013/152786
_version_ 1782278263978065920
author Pirillo, Angela
Norata, Giuseppe Danilo
Catapano, Alberico Luigi
author_facet Pirillo, Angela
Norata, Giuseppe Danilo
Catapano, Alberico Luigi
author_sort Pirillo, Angela
collection PubMed
description Oxidized low-density lipoprotein (OxLDL) contributes to the atherosclerotic plaque formation and progression by several mechanisms, including the induction of endothelial cell activation and dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation. Vascular wall cells express on their surface several scavenger receptors that mediate the cellular effects of OxLDL. The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the main OxLDL receptor of endothelial cells, and it is expressed also in macrophages and smooth muscle cells. LOX-1 is almost undetectable under physiological conditions, but it is upregulated following the exposure to several proinflammatory and proatherogenic stimuli and can be detected in animal and human atherosclerotic lesions. The key contribution of LOX-1 to the atherogenic process has been confirmed in animal models; LOX-1 knockout mice exhibit reduced intima thickness and inflammation and increased expression of protective factors; on the contrary, LOX-1 overexpressing mice present an accelerated atherosclerotic lesion formation which is associated with increased inflammation. In humans, LOX-1 gene polymorphisms were associated with increased susceptibility to myocardial infarction. Inhibition of the LOX-1 receptor with chemicals or antisense nucleotides is currently being investigated and represents an emerging approach for controlling OxLDL-LOX-1 mediated proatherogenic effects.
format Online
Article
Text
id pubmed-3723318
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37233182013-08-09 LOX-1, OxLDL, and Atherosclerosis Pirillo, Angela Norata, Giuseppe Danilo Catapano, Alberico Luigi Mediators Inflamm Review Article Oxidized low-density lipoprotein (OxLDL) contributes to the atherosclerotic plaque formation and progression by several mechanisms, including the induction of endothelial cell activation and dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation. Vascular wall cells express on their surface several scavenger receptors that mediate the cellular effects of OxLDL. The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the main OxLDL receptor of endothelial cells, and it is expressed also in macrophages and smooth muscle cells. LOX-1 is almost undetectable under physiological conditions, but it is upregulated following the exposure to several proinflammatory and proatherogenic stimuli and can be detected in animal and human atherosclerotic lesions. The key contribution of LOX-1 to the atherogenic process has been confirmed in animal models; LOX-1 knockout mice exhibit reduced intima thickness and inflammation and increased expression of protective factors; on the contrary, LOX-1 overexpressing mice present an accelerated atherosclerotic lesion formation which is associated with increased inflammation. In humans, LOX-1 gene polymorphisms were associated with increased susceptibility to myocardial infarction. Inhibition of the LOX-1 receptor with chemicals or antisense nucleotides is currently being investigated and represents an emerging approach for controlling OxLDL-LOX-1 mediated proatherogenic effects. Hindawi Publishing Corporation 2013 2013-07-10 /pmc/articles/PMC3723318/ /pubmed/23935243 http://dx.doi.org/10.1155/2013/152786 Text en Copyright © 2013 Angela Pirillo et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pirillo, Angela
Norata, Giuseppe Danilo
Catapano, Alberico Luigi
LOX-1, OxLDL, and Atherosclerosis
title LOX-1, OxLDL, and Atherosclerosis
title_full LOX-1, OxLDL, and Atherosclerosis
title_fullStr LOX-1, OxLDL, and Atherosclerosis
title_full_unstemmed LOX-1, OxLDL, and Atherosclerosis
title_short LOX-1, OxLDL, and Atherosclerosis
title_sort lox-1, oxldl, and atherosclerosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723318/
https://www.ncbi.nlm.nih.gov/pubmed/23935243
http://dx.doi.org/10.1155/2013/152786
work_keys_str_mv AT pirilloangela lox1oxldlandatherosclerosis
AT noratagiuseppedanilo lox1oxldlandatherosclerosis
AT catapanoalbericoluigi lox1oxldlandatherosclerosis